
EquityIndex FundsVery High Risk
Direct
NAV (17-Apr-26)
Returns (Since Inception)
Fund Size
₹53 Cr
Expense Ratio
0.39%
ISIN
INF247L01BI6
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
22 Aug 2022
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+13.33%
— (Cat Avg.)
3 Years
+19.56%
— (Cat Avg.)
Since Inception
+16.83%
— (Cat Avg.)
| Equity | ₹53.16 Cr | 99.88% |
| Others | ₹0.06 Cr | 0.12% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Infosys Ltd | Equity | ₹3.34 Cr | 6.27% |
| Tata Consultancy Services Ltd | Equity | ₹3.26 Cr | 6.12% |
| Hindustan Unilever Ltd | Equity | ₹3.24 Cr | 6.10% |
| ITC Ltd | Equity | ₹3.17 Cr | 5.96% |
| Hero MotoCorp Ltd | Equity | ₹3.09 Cr | 5.81% |
| Cummins India Ltd | Equity | ₹3.08 Cr | 5.79% |
| Britannia Industries Ltd | Equity | ₹2.97 Cr | 5.59% |
| Hindustan Aeronautics Ltd Ordinary Shares | Equity | ₹2.96 Cr | 5.57% |
| GE Vernova T&D India Ltd | Equity | ₹2.95 Cr | 5.55% |
| Nestle India Ltd | Equity | ₹2.89 Cr | 5.43% |
| HDFC Asset Management Co Ltd | Equity | ₹2.55 Cr | 4.78% |
| Suzlon Energy Ltd | Equity | ₹2.54 Cr | 4.77% |
| Dixon Technologies (India) Ltd | Equity | ₹2.09 Cr | 3.93% |
| Marico Ltd | Equity | ₹1.91 Cr | 3.59% |
| National Aluminium Co Ltd | Equity | ₹1.84 Cr | 3.45% |
| Page Industries Ltd | Equity | ₹1.34 Cr | 2.51% |
| Hindustan Zinc Ltd | Equity | ₹1.3 Cr | 2.44% |
| Colgate-Palmolive (India) Ltd | Equity | ₹1.14 Cr | 2.14% |
| Mazagon Dock Shipbuilders Ltd | Equity | ₹0.84 Cr | 1.57% |
| Abbott India Ltd | Equity | ₹0.83 Cr | 1.56% |
| Nippon Life India Asset Management Ltd Ordinary Shares | Equity | ₹0.8 Cr | 1.50% |
| Oracle Financial Services Software Ltd | Equity | ₹0.79 Cr | 1.49% |
| Indian Railway Catering And Tourism Corp Ltd | Equity | ₹0.77 Cr | 1.45% |
| ICICI Prudential Asset Management Co Ltd | Equity | ₹0.65 Cr | 1.23% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.62 Cr | 1.17% |
| Premier Energies Ltd | Equity | ₹0.58 Cr | 1.10% |
| Castrol India Ltd | Equity | ₹0.57 Cr | 1.06% |
| CRISIL Ltd | Equity | ₹0.45 Cr | 0.84% |
| Emami Ltd | Equity | ₹0.31 Cr | 0.58% |
| Gillette India Ltd | Equity | ₹0.28 Cr | 0.53% |
| Collateralized Borrowing & Lending Obligation | Cash - Collateral | ₹0.16 Cr | 0.30% |
| Net Receivables / (Payables) | Cash | ₹-0.1 Cr | 0.18% |
Large Cap Stocks
62.65%
Mid Cap Stocks
35.06%
Small Cap Stocks
2.17%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Consumer Defensive | ₹15.92 Cr | 29.91% |
| Industrials | ₹12.37 Cr | 23.25% |
| Technology | ₹10.06 Cr | 18.91% |
| Consumer Cyclical | ₹5.2 Cr | 9.77% |
| Financial Services | ₹4.45 Cr | 8.36% |
| Basic Materials | ₹3.13 Cr | 5.89% |
| Healthcare | ₹1.45 Cr | 2.73% |
| Energy | ₹0.57 Cr | 1.06% |
Standard Deviation
This fund
16.58%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.56
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
ISIN INF247L01BI6 | Expense Ratio 0.39% | Exit Load 1.00% | Fund Size ₹53 Cr | Age 3 years 7 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Quality TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,41,683 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments